News
NPCE
15.79
-0.13%
-0.02
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), NeuroPace (NPCE) and Avalo Therapeutics (AVTX)
TipRanks · 19h ago
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth
TipRanks · 23h ago
NeuroPace Earnings Call Highlights RNS Growth Momentum
TipRanks · 1d ago
NeuroPace (NPCE) Receives a Buy from Lake Street
TipRanks · 1d ago
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
TipRanks · 1d ago
Neuropace signals $99M-$101M 2026 revenue outlook while targeting 21%-23% underlying RNS growth
Seeking Alpha · 2d ago
NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga · 2d ago
NeuroPace reports Q1 EPS (20c), consensus (23c)
TipRanks · 2d ago
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
TipRanks · 2d ago
NeuroPace reports Q1 results
Seeking Alpha · 2d ago
NeuroPace Q1 revenue rises 20%, beats estimates, raises 2026 outlook
Reuters · 2d ago
*NeuroPace Non-GAAP Operating Expenses Outlook Excludes Approximately $10M in Stk-based Compensation, a Non-Cash Expense >NPCE
Dow Jones · 2d ago
*NeuroPace Reiterate Full Yr non-GAAP Operating Expenses to Be Between $90 M and $92 M >NPCE
Dow Jones · 2d ago
*NeuroPace Raises 2026 View To Rev $99M-$101M >NPCE
Dow Jones · 2d ago
*NeuroPace Reiterate Full Yr non-GAAP Gross Margin Between 81.5% and 82.5% >NPCE
Dow Jones · 2d ago
*NeuroPace 1Q Rev $22.1M Vs. />NPCE
Dow Jones · 2d ago
Press Release: NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Dow Jones · 2d ago
NeuroPace Inc.: Q1 Earnings Snapshot
Barchart · 2d ago
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Barchart · 2d ago
Weekly Report: what happened at NPCE last week (0504-0508)?
Weekly Report · 3d ago
More
Webull provides a variety of real-time NPCE stock news. You can receive the latest news about Neuropace Inc through multiple platforms. This information may help you make smarter investment decisions.
About NPCE
NeuroPace, Inc. is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company's RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. The Company's RNS System includes its RNS neurostimulator, its cortical strip leads and depth leads, and its Patient Remote Monitor, as well as other implantable and non-implantable accessories. The Company's product offerings also include Physician Tablet, Patient Data Management System (PDMS) and nSight Platform, which facilitate ongoing patient monitoring and streamline patient support. The PDMS is an online database.